
Millions of people ‘could be denied weight-loss jabs due to flawed NHS guidance'
King's Fund senior analyst Danielle Jefferies said Body Mass Index (BMI) measures, which are used to determine obesity levels, are primarily based on research for White European or American people.
That means they do not account for the inherited ethnic differences of people from Black, Asian, Brown, dual heritage or indigenous ethnicities – differences that can mean some groups are more likely to develop some health conditions.
The 2021 census for England and Wales showed 1.3 million people listed themselves as 'other' for their ethnic group, while 1.7 million people listed themselves in 'mixed or multiple' categories.
Ms Jefferies said that meant the current BMI thresholds 'potentially do not fully work for up to 3 million people in the UK', meaning they could miss out on treatments because they have a lower BMI than is required for some treatments.
The warning comes as the NHS is set to roll out access to weight-loss jab, Mounjaro, to 250,000 patients a year over the next 12 years.
Access to Mounjaro is based on strict measures, including that a person has a BMI of over 40. And other NHS treatments, such as IVF, bariatric surgery, and joint replacement surgery, are also managed based on a person's BMI.
Currently, BMI guidelines for people from black, Asian and Middle Eastern backgrounds are lowered to account for health risks that occur at a lower BMI than for white people. But the same is not done for those in these mixed heritage groups.
Ms Jeffries said: 'The current NICE guidelines take a broad-brush approach by recommending lower BMI thresholds for anyone of 'Black, Asian or Middle Eastern background', which effectively includes almost everyone who is not 'White'.
'This creates some knotty issues. First, because it leaves some people wondering if they are 'white enough' to use the old thresholds, which is a subjective and problematic way to categorise people from global majority ethnic backgrounds.'
'For example, does this include people who identify as Latino, white Middle Eastern, or Hispanic? Or does this include someone who is mixed and has one grandparent who is Black or Asian and the rest White?'
Ms Jefferies said the NHS BMI calculator automatically gives patients who identify as 'other white ethnic group', for example, someone who could identify as Latino, a higher threshold as if they were white.
She said this can have 'real-world consequences' and including or excluding an ethnic group from the threshold adjustment could 'significantly impact national obesity figures and change how we measure health inequalities between different ethnicities'.
'For individuals, lower BMI thresholds could be life-changing. For the average-height adult, the cut-off point for being obese for people from a White ethnicity is more than a stone heavier than for people from a 'Black, Asian or Middle Eastern background'. That could be significant if that person was sat in a GP appointment asking whether they qualify for bariatric surgery or weight loss drugs, or if they are healthy enough to receive NHS-funded IVF, ' she added.
On Thursday, it was revealed that the price of Mounjaro will nearly triple for private patients in the UK, after the US-owned company equalised costs in markets across the globe.
A month's supply of the highest doses of the ' King Kong ' of weight loss medicine will rise from £122 to £330 - an increase of 170 per cent. However, drug manufacturer Lilly said it would not raise the price paid by the NHS, and it was working with private healthcare providers to maintain access to the jab.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Telegraph
15 minutes ago
- Telegraph
Fat jab price rise could fuel surge in dangerous fakes
Experts have warned people against trying to beat the Mounjaro price rise by turning to black market weight-loss jabs. Dealers are importing the copycat drugs from Chinese labs and selling them on social media and in beauty salons. Drug crime specialists expect a rise in the number of illicit sales in the wake of 170 per cent price rises due to Donald Trump's tariffs, designed to make medications cheaper for Americans. Steroid dealers have reacted to the cost of private weight-loss injections and NHS supply bottlenecks by turning to the black market. Chinese laboratories can imitate the real drugs and sell them online for as little as £1.50 a vial, with dealers buying them in bulk and selling them on for profit. Mounjaro, the weight-loss medication made by Eli Lilly, has increased in price to as much as £330 for a month's supply. The US-based company's product is the most effective injection on the market. Dr Luke Turnock, a criminologist at the University of Lincoln who specialises in the sale of enhancement drugs, warned that this would see many people turn to imported imitations sold cheaply online. 'I would definitely expect the price rise to lead to more people looking to the illicit market,' he told The Telegraph. 'If you're paying £330 for a prescription and you see something advertised for £110, then you would think it would be stupid to keep going and getting this private prescription.' A study by Dr Turnock found that one company allegedly sells replicas of both semaglutide and tirzepatide, known commercially as Wegovy and Mounjaro, made by Novo Nordisk and Eli Lilly, respectively. But with these drugs now regulated in the UK it is technically a crime to sell them and as a result the number of fake versions available online has diminished. Next-generation weight-loss jab However, the laboratories have pivoted to selling imitation retatrutide, a next-generation weight-loss jab still in clinical trials. Also made by Eli Lilly, retatrutide could be Mounjaro's big brother and is potentially the most powerful weight-loss drug yet as a result of its triple-threat mechanism, which targets three pathways in the body. Ozempic – a drug for type 2 diabetes – works on just one, and Mounjaro only hits two of the three. Online marketing shows retatrutide to be the most effective fat injection, but it is not yet proven safe or effective. Early clinical trial data suggest it is also able to speed up how much fat a person's body burns as well as suppressing appetite and slowing down stomach emptying. But the drug is as yet unauthorised and unregulated and this provides a loophole for the Chinese laboratories who can sell their product under the guise of a 'research chemical'.


Daily Mail
15 minutes ago
- Daily Mail
Brighton fan tragically dies after falling ill in the stands during Premier League match with Fulham
A 72-year-old Brighton supporter has died after becoming unwell during the second half of Saturday's Premier League fixture against Fulham. The man, who was in the upper tier of the East Stand at the Amex Stadium, received prolonged CPR and defibrillation from medics at the scene but passed away following the conclusion of the match, which ended in a 1-1 draw. Brighton chief executive Paul Barber said: 'This was an incredibly sad end to the match this afternoon, and our deepest sympathies and condolences go out to the family and friends of the gentleman who lost his life. 'While the gentleman concerned is foremost in our minds, we are also aware that it was an emotional and distressing situation for staff and supporters in the direct vicinity. Over the coming days we will ensure those affected are properly supported.' Brighton's safety team, with the support of Sussex Police and the Premier League, opted not to stop the game because the majority of fans and both sets of players were unaware of the incident. It was felt any stoppage in play would have brought further attention to the scene and potentially impacted resuscitation attempts, as well as creating possible complications had the man responded and required rapid transportation to hospital.


Daily Mail
15 minutes ago
- Daily Mail
BBC is forced into embarrassing U-turn over 'false statistics' on Lucy Letby Panorama documentary after 'sloppy and amateurish' journalism
The BBC has been forced to correct and re-edit a Panorama programme on Lucy Letby after being accused of 'sloppy and amateurish' journalism and producing 'false statistics'. The documentary repeated discredited claims that when Letby worked as a nurse at Liverpool Women's Hospital between 2012 and 2015, the dislodgement of breathing tubes occurred at a rate 40 times higher than normal during her shifts. The claims had first been aired by Richard Baker KC, who represented the victims' families at the Thirlwall Inquiry, but were heavily contested by Jane Hutton, a professor of statistics at Warwick University, who wrote to the inquiry to express her 'concern at your very poor presentation of statistics relating to accidental dislodgement of endotracheal tubes'. Professor Hutton wrote: 'Your statements implied that an evaluation of shifts shows a substantial increase in events when Letby was on shift. This is a fine example of statistical illiteracy which can mislead juries and the general public.' However, Monday's Panorama, presented by Judith Moritz and Jonathan Coffey, described the figures as 'empirical' and suggested they damaged Letby's claims of innocence. The presenters are this month publishing an updated paperback version of their book, Unmasking Lucy Letby, which partly back-peddles on the original version's presumption of Letby's guilt. After several experts, including Professor Hutton, complained to the BBC about the segment, the corporation has now retracted the figure and edited the version of the programme available on iPlayer. In a statement released in response to an inquiry from The Mail on Sunday, the BBC said: 'We stated that babies' breathing tubes came out 40 times more often than normal when Lucy Letby was on shift. 'We have now removed that line from the programme and some associated commentary. We have also made clear that Lucy Letby was in training during both periods at the Liverpool Women's Hospital. 'We originally stated that her supporters questioned the review's findings around Liverpool Women's Hospital, and this has now been changed to say that critics say the hospital's findings are not credible and that there are any number of reasons why breathing tubes could become dislodged more often.' Dr Amy Wilson, a lecturer in statistics at Edinburgh University, described the segment as 'very concerning'. She told the corporation in a formal complaint: 'You state that the 1 per cent background rate is per ventilated baby per shift (a 'ventilation shift') and yet you compare this to a 40 per cent 'per shift' rate for Letby. 'This comparison is incorrect – Letby's rate should also be calculated as per ventilated baby per shift. Using the assumptions in your programme of ten ventilated babies per shift and 50 shifts, this would mean Letby was present for 500 ventilation shifts with 20 dislodgements. 'She would then have a rate of 4 per cent per ventilated baby per shift, not 40 per cent. The assumptions used also need to be checked – for example, if there were more than ten ventilated babies per shift, Letby's rate would be lower still.' Mark McDonald, Letby's lawyer – who says he was rebuffed by the BBC when he warned them not to air the statistic – said: 'The documentary was sloppy, amateurish and full of errors. 'It made mistakes on statistics and failed on basic maths when it came to incidents at the hospital. This may have gone down well at a literary festival to sell the presenters' new book but when it comes to journalism it was grossly misleading. 'The most egregious failing yet again was in producing false statistics which were used to implicate Lucy in further invented crimes. The statistics weren't just false, they were internally illogical.'